Skip to content 
Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company's primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation. It also develops APG-2575, an oral administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors; APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein interactions to treat solid tumors and hematological malignancies; and APG-1252, a small molecule drug to restore apoptosis through dual inhibition of the Bcl-2 and Bcl-xL proteins for the treatment of small-cell lung cancer, non-small cell lung cancer, neuroendocrine tumor, and non-Hodgkin's lymphoma. In addition, the company is developing APG-1387, a small-molecule inhibitor of apoptosis proteins for advanced solid tumors and chronic HBV infection; APG-2449, an oral inhibitor of FAK, ROS1, and ALK kinases; APG-5918, an orally available and selective embryonic ectoderm development inhibitor. In addition, it is involved in medical research and development; clinical development; clinical trials operations; venture capital investment; rental of buildings; and provision of science and technology promotion services. The company has collaboration relationships with biotechnology and pharmaceutical companies; and research institutions. Ascentage Pharma Group International was founded in 2009 and is headquartered in Suzhou, China. more
| Time Frame | AAPG | Sector | S&P500 |
|---|---|---|---|
| 1-Week Return | -2.85% | -0.03% | -1.38% |
| 1-Month Return | -14.22% | 0.59% | -1.81% |
| 3-Month Return | -29.26% | 3.23% | 1.38% |
| 6-Month Return | -42.11% | 18.29% | 5.68% |
| 1-Year Return | 38.01% | 7.71% | 11.74% |
| 3-Year Return | 37.05% | 18.03% | 65.15% |
| Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | 5YR TREND | |
|---|---|---|---|---|---|---|
| Total Revenue | 12.45M | 27.91M | 209.71M | 221.98M | 980.65M | [{"date":"2020-12-31","value":1.27,"profit":true},{"date":"2021-12-31","value":2.85,"profit":true},{"date":"2022-12-31","value":21.38,"profit":true},{"date":"2023-12-31","value":22.64,"profit":true},{"date":"2024-12-31","value":100,"profit":true}] |
| Cost of Revenue | 1.97M | 3.33M | 22.00M | 30.54M | 29.09M | [{"date":"2020-12-31","value":6.44,"profit":true},{"date":"2021-12-31","value":10.9,"profit":true},{"date":"2022-12-31","value":72.02,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":95.23,"profit":true}] |
| Gross Profit | 10.48M | 24.58M | 187.71M | 191.44M | 951.57M | [{"date":"2020-12-31","value":1.1,"profit":true},{"date":"2021-12-31","value":2.58,"profit":true},{"date":"2022-12-31","value":19.73,"profit":true},{"date":"2023-12-31","value":20.12,"profit":true},{"date":"2024-12-31","value":100,"profit":true}] |
| Gross Margin | 84.21% | 88.08% | 89.51% | 86.24% | 97.03% | [{"date":"2020-12-31","value":86.78,"profit":true},{"date":"2021-12-31","value":90.77,"profit":true},{"date":"2022-12-31","value":92.25,"profit":true},{"date":"2023-12-31","value":88.88,"profit":true},{"date":"2024-12-31","value":100,"profit":true}] |
| Operating Expenses | 674.42M | 894.42M | 1.04B | 1.06B | 1.32B | [{"date":"2020-12-31","value":51.04,"profit":true},{"date":"2021-12-31","value":67.69,"profit":true},{"date":"2022-12-31","value":78.52,"profit":true},{"date":"2023-12-31","value":80.53,"profit":true},{"date":"2024-12-31","value":100,"profit":true}] |
| Operating Income | (663.94M) | (869.84M) | (849.81M) | (872.64M) | (369.73M) | [{"date":"2020-12-31","value":-66394100000,"profit":false},{"date":"2021-12-31","value":-86983500000,"profit":false},{"date":"2022-12-31","value":-84981000000,"profit":false},{"date":"2023-12-31","value":-87263600000,"profit":false},{"date":"2024-12-31","value":-36973000000,"profit":false}] |
| Total Non-Operating Income/Expense | (12.54M) | 27.96M | (80.42M) | (123.87M) | (52.14M) | [{"date":"2020-12-31","value":-44.86,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-287.61,"profit":false},{"date":"2023-12-31","value":-443.02,"profit":false},{"date":"2024-12-31","value":-186.47,"profit":false}] |
| Pre-Tax Income | (675.45M) | (832.25M) | (887.17M) | (932.86M) | (395.25M) | [{"date":"2020-12-31","value":-67544800000,"profit":false},{"date":"2021-12-31","value":-83224900000,"profit":false},{"date":"2022-12-31","value":-88717200000,"profit":false},{"date":"2023-12-31","value":-93286200000,"profit":false},{"date":"2024-12-31","value":-39525500000,"profit":false}] |
| Income Taxes | 2.16M | (49.83M) | (4.25M) | (7.15M) | 10.43M | [{"date":"2020-12-31","value":20.7,"profit":true},{"date":"2021-12-31","value":-477.94,"profit":false},{"date":"2022-12-31","value":-40.75,"profit":false},{"date":"2023-12-31","value":-68.59,"profit":false},{"date":"2024-12-31","value":100,"profit":true}] |
| Income After Taxes | (677.61M) | (782.42M) | (882.92M) | (925.71M) | (405.68M) | [{"date":"2020-12-31","value":-67760600000,"profit":false},{"date":"2021-12-31","value":-78242400000,"profit":false},{"date":"2022-12-31","value":-88292400000,"profit":false},{"date":"2023-12-31","value":-92571200000,"profit":false},{"date":"2024-12-31","value":-40568000000,"profit":false}] |
| Income From Continuous Operations | (677.61M) | (782.42M) | (882.92M) | (925.71M) | (405.68M) | [{"date":"2020-12-31","value":-67760600000,"profit":false},{"date":"2021-12-31","value":-78242400000,"profit":false},{"date":"2022-12-31","value":-88292400000,"profit":false},{"date":"2023-12-31","value":-92571200000,"profit":false},{"date":"2024-12-31","value":-40568000000,"profit":false}] |
| Income From Discontinued Operations | - | - | - | - | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}] |
| Net Income | (677.61M) | (782.42M) | (882.92M) | (925.64M) | (405.43M) | [{"date":"2020-12-31","value":-67760600000,"profit":false},{"date":"2021-12-31","value":-78242400000,"profit":false},{"date":"2022-12-31","value":-88292400000,"profit":false},{"date":"2023-12-31","value":-92563700000,"profit":false},{"date":"2024-12-31","value":-40543300000,"profit":false}] |
| EPS (Diluted) | - | - | - | - | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}] |
These ratios help you determine the liquidity of the company. Higher is better.
| AAPG | |
|---|---|
| Cash Ratio | 1.34 |
| Current Ratio | 1.54 |
| Quick Ratio | 1.53 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
| AAPG | |
|---|---|
| ROA (LTM) | -22.77% |
| ROE (LTM) | -159.65% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
| AAPG | |
|---|---|
| Debt Ratio Lower is generally better. Negative is bad. | 0.78 |
| Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.22 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
| AAPG | |
|---|---|
| Trailing PE | NM |
| Forward PE | NM |
| P/S (TTM) | 5.70 |
| P/B | 22.99 |
| EV/R | 40.06 |
| EV/Ebitda | NM |
Ascentage Pharma Group International (AAPG) share price today is $23.82
Yes, Indians can buy shares of Ascentage Pharma Group International (AAPG) on Vested. To buy
Yes, you can purchase fractional shares of Ascentage Pharma Group International (AAPG) via the Vested app. You can start investing in Ascentage Pharma Group International (AAPG) with a minimum investment of $1.
You can invest in shares of Ascentage Pharma Group International (AAPG) via Vested in three simple steps:
The 52-week high price of Ascentage Pharma Group International (AAPG) is $48.45. The 52-week low price of Ascentage Pharma Group International (AAPG) is $17.55.
The price-to-earnings (P/E) ratio of Ascentage Pharma Group International (AAPG) is
The price-to-book (P/B) ratio of Ascentage Pharma Group International (AAPG) is 22.99
The dividend yield of Ascentage Pharma Group International (AAPG) is 0.00%
The market capitalization of Ascentage Pharma Group International (AAPG) is $2.21B
The stock symbol (or ticker) of Ascentage Pharma Group International is AAPG
Consider the share price of Ascentage Pharma Group International as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether Ascentage Pharma Group International has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.
When investing in Ascentage Pharma Group International shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the Ascentage Pharma Group International stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.
Rather than merely checking the share price of Ascentage Pharma Group International and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that Ascentage Pharma Group International stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.
Link copied 
